---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-237908"
form_type: "8-K"
ticker: "CGON"
cik: "0001991792"
company_name: "CG Oncology, Inc."
filed_at: "2026-05-26T12:00:15+00:00"
generated_at: "2026-05-26T12:11:05.047967+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# CG Oncology President & COO Bellete to depart June 30; CEO Kuan becomes President

## Summary
- Ambaw Bellete, President & COO, agreed to separation effective June 30, 2026; severance per existing employment agreement.
- Arthur Kuan appointed as President in addition to his other roles, effective upon Bellete's departure.
- Company has initiated a search for a Chief Commercial Officer.
- No reason for departure given; transition appears orderly.

## SEC filing metadata
- accession: 0001193125-26-237908
- form_type: 8-K
- ticker: CGON
- cik: 0001991792
- company_name: CG Oncology, Inc.
- filed_at: 2026-05-26T12:00:15+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1991792/000119312526237908/0001193125-26-237908-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1991792/000119312526237908/ck0001991792-20260520.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-237908
- JSON: https://secwatch.observer/filing/0001193125-26-237908.json
- Plain text: https://secwatch.observer/filing/0001193125-26-237908.txt

## Source-grounded claims
- claim_id: 1b56bdd249
  claim: Arthur Kuan was appointed as President at CG Oncology, Inc..
  evidence_excerpt: On May 20, 2026, the Company’s Board of Directors also approved the appointment of Arthur Kuan as President of the Company, in addition to his other positions, in connection with Mr. Bellete’s separation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1991792/000119312526237908/0001193125-26-237908-index.htm
- claim_id: 69a3f0621d
  claim: Ambaw Bellete departed as President & Chief Operating Officer at CG Oncology, Inc..
  evidence_excerpt: On May 20, 2026, CG Oncology, Inc. (the “ Company ”) and Ambaw Bellete, the Company’s President & Chief Operating Officer of the Company, agreed to his separation from the Company to be effective June 30, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1991792/000119312526237908/0001193125-26-237908-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.